Javascript must be enabled to continue!
Efficacy and safety of vortioxetine in cardiological patients
View through CrossRef
IntroductionThe most important conditions for the using of antidepressants in cardiological practice are good tolerability, minimal interaction with other drugs, and the absence of a toxic effect. All of the above qualities among antidepressants have a multimodal antidepressant – vortioxetine.ObjectivesEvaluation of the efficacy and safety of vortioxetine in the treatment of concomitant depressive disorders in cardiological patients.Methods37 patients aged 45-66 years who were admitted for inpatient treatment at the Regional Clinical Cardiology Dispensary with a diagnosis of “coronary heart disease, Angina pectoris II-III FC” were examined. Upon the hospitalization, they were consulted by a psychiatrist. During the consultation, the patients were diagnosed with a Major depressive disorder, single episode, moderate (F 32.1 according to ICD – 10). Therapy of depressive disorder was carried out in average therapeutic doses with vortioxetine for 8 weeks. To evaluate the efficacy, scales and questionnaires were used: HADS, PDQ–20, CGI–C, SF–36. Statistical processing of the material was carried out using a package of applied statistical programs: Excel, Word (version 2108).ResultsAnalysis of the results of assessing the severity of depressive and anxiety manifestations on the HADS scale and the level of cognitive functioning using the PDQ questionnaire allowed us to state that at the end of 8 weeks of therapy with vortioxetine, 89% of patients showed significant clinical improvement. The positive dynamics of patients is confirmed by data on the CGI–C scale. The answers to the SF–36 questionnaire indicate an improvement in the life quality indicators. Statistically significant changes were observed in the parameters “Physical condition”, “Mental health” and “Vital activity”.The tolerability of vortioxetine in all patients was good, side effects in 13.5% of the subjects in the form of dizziness, nausea and daytime drowsiness were reduced within 1 week.There were no significant changes in the biochemical parameters of blood, coagulogram, electrolyte composition. When assessing the indicators of blood pressure, heart rate, there was a significant improvement in indicators by the end of the research. In 8 weeks, the frequency of angina attacks and arrhythmias significantly was decreased.ConclusionsWhen prescribing vortioxetine to patients with cardiological pathology for 8 weeks, there was distinct positive dynamics both in terms of indicators of the cardiovascular system, and in the emotional sphere, cognitive and social functioning.Disclosure of InterestNone Declared
Title: Efficacy and safety of vortioxetine in cardiological patients
Description:
IntroductionThe most important conditions for the using of antidepressants in cardiological practice are good tolerability, minimal interaction with other drugs, and the absence of a toxic effect.
All of the above qualities among antidepressants have a multimodal antidepressant – vortioxetine.
ObjectivesEvaluation of the efficacy and safety of vortioxetine in the treatment of concomitant depressive disorders in cardiological patients.
Methods37 patients aged 45-66 years who were admitted for inpatient treatment at the Regional Clinical Cardiology Dispensary with a diagnosis of “coronary heart disease, Angina pectoris II-III FC” were examined.
Upon the hospitalization, they were consulted by a psychiatrist.
During the consultation, the patients were diagnosed with a Major depressive disorder, single episode, moderate (F 32.
1 according to ICD – 10).
Therapy of depressive disorder was carried out in average therapeutic doses with vortioxetine for 8 weeks.
To evaluate the efficacy, scales and questionnaires were used: HADS, PDQ–20, CGI–C, SF–36.
Statistical processing of the material was carried out using a package of applied statistical programs: Excel, Word (version 2108).
ResultsAnalysis of the results of assessing the severity of depressive and anxiety manifestations on the HADS scale and the level of cognitive functioning using the PDQ questionnaire allowed us to state that at the end of 8 weeks of therapy with vortioxetine, 89% of patients showed significant clinical improvement.
The positive dynamics of patients is confirmed by data on the CGI–C scale.
The answers to the SF–36 questionnaire indicate an improvement in the life quality indicators.
Statistically significant changes were observed in the parameters “Physical condition”, “Mental health” and “Vital activity”.
The tolerability of vortioxetine in all patients was good, side effects in 13.
5% of the subjects in the form of dizziness, nausea and daytime drowsiness were reduced within 1 week.
There were no significant changes in the biochemical parameters of blood, coagulogram, electrolyte composition.
When assessing the indicators of blood pressure, heart rate, there was a significant improvement in indicators by the end of the research.
In 8 weeks, the frequency of angina attacks and arrhythmias significantly was decreased.
ConclusionsWhen prescribing vortioxetine to patients with cardiological pathology for 8 weeks, there was distinct positive dynamics both in terms of indicators of the cardiovascular system, and in the emotional sphere, cognitive and social functioning.
Disclosure of InterestNone Declared.
Related Results
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
PREVIDA- IMPACT OF VORTIOXETINE ON MAJOR DEPRESSIVE DISORDER AND PERCEIVED COGNITIVE DYSFUNCTION: A MULTICENTER STUDY
PREVIDA- IMPACT OF VORTIOXETINE ON MAJOR DEPRESSIVE DISORDER AND PERCEIVED COGNITIVE DYSFUNCTION: A MULTICENTER STUDY
Objective: To find out how common cognitive impairment is in people with major depressive disorder (MDD) and assess how well vortioxetine works for treating both cognitive dysfunct...
New insights into chronic pain management based on biopsychosocial model
New insights into chronic pain management based on biopsychosocial model
The biopsychosocial model of pain dominates the scientific community’s understanding of chronic pain. Chronic pain is considered a different form of depression. In this study, pain...
SUICIDAL IDEATION IN DEPRESSED PATIENTS AND THERAPEUTIC ROLE OF VORTIOXETINE: SECONDARY ANALYSIS OF A LARGE PROSPECTIVE STUDY
SUICIDAL IDEATION IN DEPRESSED PATIENTS AND THERAPEUTIC ROLE OF VORTIOXETINE: SECONDARY ANALYSIS OF A LARGE PROSPECTIVE STUDY
OBJECTIVES
To explore the association of different variables with suicidal ideation and the role of vortioxetine in managing suicidal ideation in depressed patients in Pakistan.
...
A Comparative Efficacy of Antidepressants in the Treatment of Major Depressive Disorder: A Systematic Review and Meta-Analysis
A Comparative Efficacy of Antidepressants in the Treatment of Major Depressive Disorder: A Systematic Review and Meta-Analysis
Study background & objective: Major Depressive Disorder (MDD) affects about 280, 000, 000 people globally, with a higher incidence among females than males. The increasing inci...
Vortioxetine for generalised anxiety disorder in adults
Vortioxetine for generalised anxiety disorder in adults
INTRODUCTION The currently accepted psychopharmacological treatment for generalised anxiety disorder in adults is associated with several adverse effects which threaten its accepta...
An anti-depressant drug vortioxetine suppresses malignant glioblastoma cell growth
An anti-depressant drug vortioxetine suppresses malignant glioblastoma cell growth
AbstractGlioblastoma (GBM) stands as the predominant primary malignant brain tumor in adults, characterized by an exceedingly grim prognosis. Urgent efforts are essential to pionee...
Effects of Dietary Flavonoids on the Metabolism of Vortioxetine and
its Potential Mechanism
Effects of Dietary Flavonoids on the Metabolism of Vortioxetine and
its Potential Mechanism
Introduction:
Quercetin and apigenin are two common dietary flavonoids widely found in
foods and fruits. Quercetin and apigenin can act as the inhibitors of CYP450 enzymes, which m...

